Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of …
J Zhang, G Cao, Y Huo, LL Guarneiri… - The Journal of …, 2025 - Wiley Online Library
Obicetrapib is a selective cholesteryl ester transfer protein (CETP) inhibitor. Previous
research has demonstrated similar pharmacokinetic (PK) responses to single doses of …
research has demonstrated similar pharmacokinetic (PK) responses to single doses of …
Genetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study
B Su, Z Fan, J Wu, H Zhan - Scientific Reports, 2025 - nature.com
Previous studies have found that dyslipidemia is a risk factor for pancreatic cancer (PC), and
that lipid-lowering drugs may reduce the risk of PC. However, it is not clear whether …
that lipid-lowering drugs may reduce the risk of PC. However, it is not clear whether …
CETP inhibition Reduces Cardiovascular Events by Lowering of Cumulative LDL Exposure: Reconciling Evidence from Human Genetics and Clinical Trials
Background: Genetic studies consistently demonstrate that individuals born with reduced
Cholesteryl Ester Transfer Protein (CETP) activity experience lower rates of atherosclerotic …
Cholesteryl Ester Transfer Protein (CETP) activity experience lower rates of atherosclerotic …
Integrating multi-modal omics to identify therapeutic atherosclerosis pathways for coronary heart disease
relevant tissues and may contain relevant therapeutic leads. We integrated data on urinary
metabolism breakdown products, plasma proteins, atherosclerotic plaque tissue, and single …
metabolism breakdown products, plasma proteins, atherosclerotic plaque tissue, and single …
Immune cell-mediated CETP gene and the causal relationship with ischemic stroke disease risk: Mendelian randomization analysis with mediation effect assessment
H Yuan, X Feng, J Lin, C Huang, M Huang, C Duan - 2025 - researchsquare.com
Background: The advancement of cholesterol ester transfer protein inhibitors in the
treatment of coronary heart disease (CHD) has thus far failed to produce approved …
treatment of coronary heart disease (CHD) has thus far failed to produce approved …
[HTML][HTML] Hao Yuan 1 **n Feng 1 jiancheng Lin 1 Chi Huang
M Huang, C Duan - assets-eu.researchsquare.com
Background: The advancement of cholesterol ester transfer protein inhibitors in the
treatment of coronary heart disease (CHD) has thus far failed to produce approved …
treatment of coronary heart disease (CHD) has thus far failed to produce approved …
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity
MH Davidson, A Hsieh… - Current Opinion in …, 2024 - journals.lww.com
At present, there is robust clinical evidence to support the benefits of reducing CETP activity
for ASCVD risk reduction, and plausibility exists for the promotion of longevity by reducing …
for ASCVD risk reduction, and plausibility exists for the promotion of longevity by reducing …